Company / Net Income
Larimar Therapeutics, Inc. Net Income History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$52.0M
FY2019
5-year range
-$74.3M / -$14.0M
FY2015-FY2019
Trend
+10.1%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$74M to -$52M over the past 2 years.
Based on SEC 10-K filings.
-$52M in FY2019.
Improved from -$74M to -$52M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, net income increased 10.1% year-over-year.
- Peak net income was recorded in FY2014.
- Lowest net income in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | -$52.0M | +10.1% |
| FY2018 | -$57.9M | +22.1% |
| FY2017 | -$74.3M | -103.6% |
| FY2016 | -$36.5M | -160.1% |
| FY2015 | -$14.0M | -1.1% |
| FY2014 | -$13.9M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026